Phase 3 study of daratumumab/bortezomib/ dexamethasone (D-Vd) versus bortezomib/ dexamethasone (VD) in chinese patients (pts) with relapsed/refractory multiple myeloma (RRMM): MMY3009 (LEPUS)

Category Primary study
ConferenceHemaSphere
Year 2020
This article has no abstract
Epistemonikos ID: 20cf2af72f48931a59b20681ab090310e53d65d2
First added on: Apr 30, 2026